Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/171764
Title: Short-term mortality in end-stage heart failure patients
Author: Verdú Rotellar, Jose Maria
Calero, Esther
Abellana Sangrà, Rosa Mari
Verdú Soriano, José
Vinyoles, Ernest
Val García, José Luis del
Domingo, Mar
Muñoz, Miguel Angel
Keywords: Malalties del cor
Mortalitat
Heart diseases
Mortality
Issue Date: Sep-2020
Publisher: Elsevier España
Abstract: Objectives: This study is aimed at analyzing the impact of the main factors contributing to short and long-term mortality in patients at final stages of heart failure (HF). Setting: Patients attended at any of the 279 primary health care centers belonging to the Institut Català de la Salut, in Catalonia (Spain). Participants: Patients with Advanced HF. Design: Multicenter cohort study including 1148 HF patients followed for one-year after reaching New York Heart Association (NYHA) IV. Main measurements: The primary outcome was all-cause mortality. Multivariate logistic regression models were performed to assess the outcomes at 1, 3, 6, and 12 months. Results: Mean age of patients was 82 (SD 9) years and women represented 61.7%. A total of 135 (11.8%) and 397 (34.6%) patients died three months and one year after inclusion, respectively. Male gender, age, and decreased body mass index were associated with higher mortality at three, six and twelve months. In addition, low systolic blood pressure levels, severe reduction in glomerular filtration, malignancy, and higher doses of loop diuretics were related to higher mortality from 6 to 12 months. The most important risk factor over the whole period was presenting a body mass index lower than 20 kg/m2 (three months OR 3.06, 95% CI: 1.58---5.92; six months OR 4.42, 95% CI: 2.08---9.38; and 12 months OR 3.68, 95% CI: 1.76---7.69). Conclusions: We may conclude that male, age, and decreased body mass index determined higher short-term mortality in NYHA IV. In addition, low systolic blood pressure, reduced glomerular filtration, malignancy, and higher doses of loop diuretics contribute to increasing the risk of mortality at medium and long-term. Such variables are easily measurable and can help to decide the best way to face the most advances stages of the disease
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.aprim.2019.07.019
It is part of: Atención Primaria, 2020, vol. 52, num. 7, p. 477-487
URI: http://hdl.handle.net/2445/171764
Related resource: https://doi.org/10.1016/j.aprim.2019.07.019
ISSN: 0212-6567
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Medicina)
Articles publicats en revistes (Fonaments Clínics)

Files in This Item:
File Description SizeFormat 
694818.pdf990.7 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons